Detail akcie ANI Pharmaceuticals online

Business Summary: ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of 116 products with a variety of indications and a robust portfolio of pipeline products. It has acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. The Company sources the raw materials for its products from both domestic and international suppliers.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, ANI Pharmaceuticals Inc revenues increased 54% to $486.8M. Net income applicable to common stockholders totaled $15.5M vs. loss of $49.5M. Revenues reflect Generics Established Brands and Other segment increase of 36% to $374.7M, Rare Disease segment increase from $41.7M to $112.1M. Net Income reflects Restructuring activities decrease of 80% to $1.1M (expense).